Life science News and Research

RSS

HP awarded $30 million contract to create Texas Medicaid health information exchange

HP today announced a 52-month services agreement with the Texas Health and Human Services Commission to create a statewide Medicaid health information exchange.

12 Jan 2011

BioScale announces results of two pharmacodynamic biomarkers using assay AMMP technology

BioScale, an innovative life science company that develops, manufactures and promotes novel analytical tools enabling advancements in protein research, announced that results from the analysis of two pharmacodynamic biomarkers using the Acoustic Membrane MicroParticles assay technology on the ViBE Protein Analysis Workstation were published in the peer-reviewed Elsevier Journal of Analytical Biochemistry.

11 Jan 2011

QIAGEN to acquire minority stake in Alacris Theranostics

QIAGEN has signed an agreement for the acquisition of a strategic stake in Alacris Theranostics GmbH, a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile, and for the acquisition of an exclusive option to access all biomarkers emerging from this discovery program.

From QIAGEN Manchester Limited 11 Jan 2011

Cell Biosciences introduces FluorChem M MultiFluor for detectig multicolor fluorescent Western blots

Cell Biosciences, a provider of innovative protein analysis tools to life science researchers, today announced the launch of the latest addition to their premier line of next-generation imaging products, the FluorChem M MultiFluor system.

5 Jan 2011

DBV Technologies secures $25.5 million in Series C financing round

DBV Technologies, an emerging biotechnology company, announced today that it has secured $25.5 million (€19,4 million) in a Series C financing round. The round was co-led by new investors InnoBio Fund (managed by CDC Entreprises within FSI France Investment program) and Lundbeckfond Ventures.

5 Jan 2011

Thomson Reuters and ChemAxon enter strategic partnership

The IP Solutions business of Thomson Reuters®, the leader in intellectual property research and analysis solutions, and ChemAxon, the leader in cheminformatics software for the life sciences industry, today announced a strategic partnership whereby Thomson Reuters is providing its chemical IP Data Feeds – Markush Structures and patent data to users of ChemAxon's JChem chemical software platform.

5 Jan 2011

The Scientist examines how nonprofit, for-profit pharma groups are working together to make drugs more affordable for developing countries

"With philanthropists funneling billions of dollars into biomedical research and traditional drug discovery efforts producing fewer and fewer therapies, the line between for-profit and nonprofit life science companies is beginning to blur as both sides of the divide look for new options," The Scientist magazine writes in an article that examines the rise in collaborations between nonprofit pharmaceutical companies and for-profit groups.

4 Jan 2011

Met-FISC complex formation critical step in juvenile hormone signaling pathway

Just as raging hormones are part of the process of a child's maturation through the teen years to adulthood, juvenile hormones, a group of insect isoprenoids, play an important role as butterflies, fruit flies and mosquitoes transform their body structures as they molt from larva to pupa and then adults.

28 Dec 2010

InfraReDx to receive $862,000 as part of MLSC Tax Incentive Program

InfraReDx, Inc., a medical device company developing intelligent cardiovascular diagnostic imaging technologies, today announced that it has been selected to receive an award of nearly $862,000 as part of the Massachusetts Life Sciences Center Tax Incentive Program. In conjunction with the award, InfraReDx has committed to create 32 new jobs during 2011.

24 Dec 2010

GE Healthcare announces completion of tender offer for Clarient

GE Healthcare, a unit of General Electric Company announced today that it has completed the tender offer by GE's wholly owned subsidiary, Crane Merger Sub, Inc., for all outstanding shares of common and preferred stock of Clarient Inc., a leading player in the fast-growing molecular diagnostics sector. Clarient provides pathologists and oncologists with access to key diagnostic tests that shed light on the complex nature of various cancers.

23 Dec 2010

NanoLogix enters collaboration with Advanced Medical German Company of Kuwait

NanoLogix, an innovator in the accelerated detection and identification of microorganisms, is pleased to announce its collaboration with Advanced Medical German Company of Kuwait (AMGKWT). This alliance will support NanoLogix's market penetration goals for the Middle East, North and East Africa with the international marketing focus of Advanced Medical German Company stretching from the Middle East through Africa.

20 Dec 2010

BioNeutral Group, KHA to introduce Ogiene and Ygiene products

BioNeutral Group, Inc., a specialty life science technology-based company, today announced it is entering into discussions with the Kentucky Hospital Association (KHA) through its subsidiary Kentucky Hospital Services Corporation LLC (KHSC) to introduce BioNeutral's Ogiene™ and Ygiene™ products into its member hospital association.

20 Dec 2010

Almac recognised with 'News Flow of the Year' award

The Almac Group, one of the world's leading contract drug development and manufacturing organisations, was presented with the "News Flow of the Year" accolade at the 2010 Genesis Awards annual Gala dinner in London last week, following the company being shortlisted as a finalist in the category nominations. Now into its tenth year, Genesis is established as a leading life science networking conference.

16 Dec 2010

Domainex wins 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award

Domainex Ltd, the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award. This Award was made in recognition of Domainex's proactive work on promoting academic-industry collaborations, and was adjudicated by leading representatives of the biotechnology and pharmaceutical industries.

From Domainex 15 Dec 2010

AzTe and Zcube: Innovative treatment of chronic respiratory diseases

Zcube, Srl, the research venture of Italian pharmaceutical company Zambon Co., SpA, and Arizona Technology Enterprises (AzTE), the technology venturing arm of Arizona State University, have entered into a licensing agreement that will allow Zcube to use ASU technology to develop and commercialize next-generation medical devices that can better monitor and treat chronic respiratory diseases like asthma.

15 Dec 2010

Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors

Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR.

15 Dec 2010

Life Technologies announces launch of Ion Personal Genome Machine sequencer

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has launched its Ion Personal Genome Machine (PGM™) sequencer, the first product to use semiconductor sequencing technology. The sequencer is shipping to select sites in North America, Europe and Asia Pacific.

14 Dec 2010

Cedarlane to distribute TGR's new ELISA-One technology assay reagents in Canada and the US

TGR BioSciences, a leading global provider of advanced cell based assay technologies in the fields of cancer, kinase and GPCR research, is extremely pleased to announce a distribution partnership with Cedarlane Laboratories of Burlington, ON, Canada, a leading supplier of Life Science research reagents in North America.

13 Dec 2010

First-ever Prophylactic Cancer Vaccine Conference to be held in Tempe, Arizona

World-leading scientists, ethicists, policymakers, and cancer patient advocates will gather at Arizona State University for the first-ever Prophylactic Cancer Vaccine Conference in Tempe, Ariz., March 16-18, 2011. The conference will be a premier forum to discuss the latest developments in a radical new approach to battling cancer: the development of cancer vaccines aimed at protecting healthy individuals from the disease.

13 Dec 2010

Harvard Bioscience files two major patents in regenerative medicine

Harvard Bioscience, Inc., a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research and regenerative medicine, has filed two major patents in the field of regenerative medicine, the first covering 61 claims for its stem cell therapy injectors and the second for 338 claims for bioreactors for organ growth.

From Harvard Bioscience 10 Dec 2010